Pavaki Capital Management
Pavaki Capital Management reported 132 stocks worth $200M in its 13F filing for Q3 2026, filed Oct 26, 2026. Its largest holdings are NVDA (14.8%), CVX (10.5%) and INTU (5.3%). Compared with Q2 2026, the fund opened new positions in CAI, REAX and HII, added to NVDA, CVX and B, trimmed CGAU, SSRM and EQX and sold out of AMD, NOK and REPL.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 4 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  NVDA Nvidia Corporation | $29.7M | 14.8% | 130K | +104K (+400%) | 4 of 4 | |
| 2 |  CVX Chevron Corp New | $21M | 10.5% | 103K | +6,000 (+6%) | 4 of 4 | |
| 3 |  INTU Intuit | $10.6M | 5.3% | 39K | No change | 2 of 4 | |
| 4 |  B Barrick Mng Corp | $9.2M | 4.6% | 227K | +5,000 (+2%) | 4 of 4 | |
| 5 |  QCOM Qualcomm Inc | $9M | 4.5% | 49K | No change | 2 of 4 | |
| 6 |  REGN Regeneron Pharmaceutical | $8.6M | 4.3% | 11K | +1,400 (+14%) | 4 of 4 | |
| 7 |  MIST Milestone Pharmaceuticals in | $8.1M | 4.0% | 9.3M | +270K (+3%) | 4 of 4 | |
| 8 |  TXT Textron Inc | $6.9M | 3.5% | 91K | +6,500 (+8%) | 4 of 4 | |
| 9 |  BTG B2GOLD Corp | $6.2M | 3.1% | 1.2M | No change | 4 of 4 | |
| 10 |  ARQT Arcutis Biotherapeutics Inc | $4.9M | 2.5% | 187K | No change | 4 of 4 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 AMD Advanced Micro Devices Inc | $2.3M | 4,000 |
 NOK Nokia Corp | $930K | 70K |
 REPL Replimune Group Inc | $890K | 80K |
 INTC Intel Corp | $559K | 4,000 |
 ARIS Aris Mng Corp | $447K | 30K |
🔒 Free account: see all 9.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 CVNA Carvana Co | Call | $37.8M | 605K | 0 |
 TSLA Tesla Inc | Call | $15.8M | 45K | +1,000 |
 PLTR Palantir Technologies Inc | Call | $9.4M | 51K | 0 |
 QQQ Invesco Qqq TR | Put | $5.2M | 7,000 | −16,000 |
QQQ Invesco Qqq TR | Call | $3.3M | 4,500 | 0 |
🔒 Free account: see all 20.
Reported value
last 4 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Oct 26, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Pavaki Capital Management 13F FAQ
What does Pavaki Capital Management own?
Pavaki Capital Management reported 132 stocks worth $200M in its 13F filing for Q3 2026, filed Oct 26, 2026. Its largest holdings are NVDA (14.8%), CVX (10.5%) and INTU (5.3%). The table above lists every position in the filing (the top 10 without an account).
What did Pavaki Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 9 new positions, 10 added to, 4 trimmed and 9 sold out. New positions include CAI, REAX and HII. It sold all of AMD, NOK and REPL.
When will Pavaki Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Pavaki Capital Management's portfolio worth?
The Q3 2026 filing reports $200M in US stocks ($294M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.